세계의 임상 의사결정 지원 시스템 시장 : 구성요소, 제품, 모델, 제공 모드, 자문 모드, 설정, 유형, 용도, 지역별 예측(-2032년)

Global Clinical Decision Support System Market Research Report Information by Component (Software, Services, and Hardware) By Product (Integrated CDSS and Standalone CDSS), By Model (Knowledge-Based CDSS and Non-Knowledge-Based CDSS), By Delivery Mode (On-Premise CDSS and Cloud-Based CDSS), By Mode of Advice (Active CDSS and Passive CDSS), By Setting (Inpatient Settings and Ambulatory Care Settings) By Type (Therapeutic Clinical Decision Support Systems and Diagnostic Clinical Decision Support Systems ), By Application (Advanced Clinical Decision Support Systems and Conventional Clinical Decision Support Systems), By Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2032

Market Overview

The clinical decision support system market industry is anticipated to experience a compound annual growth rate (CAGR) of 10.54% during the forecast period, increasing from USD 3.67 billion in 2024 to USD 8.92 billion by 2032. The market is experiencing growth due to the increasing geriatric population, favorable government regulations, and the increasing demand for data-driven technologies.

The geriatric population is more susceptible to chronic diseases and necessitates frequent medical examinations and interventions. Consequently, the burden on healthcare institutions is exacerbated by the growing geriatric population. This drives the demand for technologies like CDSS to ensure the provision of efficient care. For instance, the United Nations predicts that by 2050, one in six individuals worldwide will be over the age of 65, a significant increase from one in eleven in 2019. The number of senior adults aged 65 and older is anticipated to increase to nearly 90 million in the United States by 2050, as per the Rural Health Information Hub. In addition, it is anticipated that by 2030, one in five Americans will be 65 years of age or older.

Market segment insights

Software, services, and hardware comprise the Clinical Decision Support System Market segmentation, which is based on component.

The market segmentation is determined by the products, which include Standalone CDSS and Integrated CDSS.

The market segmentation is predicated on a model that encompasses both knowledge-based and non-knowledge-based CDSS.

The Clinical Decision Support System Market segmentation is determined by the delivery mode, which encompasses On-Premises CDSS and Cloud-Based CDSS.

The market segmentation is determined by the mode of advice, which encompasses Active CDSS and Passive CDSS.

On the basis of setting, the market segmentation encompasses both inpatient and ambulatory care contexts.

Therapeutic clinical decision support systems and diagnostic clinical decision support systems comprise the Clinical Decision Support System Market segmentation.

The market segmentation is determined by the application, which encompasses both conventional and advanced clinical decision support systems.

Regional Perspectives

In 2023, the clinical decision support system market in North America held the greatest market share. This is a result of the rising incidence of chronic diseases in the North American region, including cancer, cardiovascular disorders, diabetes, obesity, and arthritis.

In Europe, the clinical decision support system market is the second highest market share, as a result of the region's access to advanced treatment facilities.

The Asia-Pacific clinical decision support system market is anticipated to experience substantial growth as a result of the growing patient population in the region, as well as the improvement of healthcare infrastructure and the prevalence of chronic diseases such as cancer, orthopedic, and cardiovascular diseases.

Major Players

Siemens (Germany), Veradigm LLC (Allscripts Healthcare Solutions Inc) (US), Oracle Corporation (US), IBM (US), Carestream Health (US), Wolters Kluwer N.V. (Netherlands), Epic Systems Corporation (US), Chang Healthcare (US), Medical Information Technology, Inc. (US), and Computer Programs and Systems, Inc (US) are among the key companies in the Clinical Decision Support System Market.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA FLOW
  • 3.2.1 DATA MINING PROCESS
• 3.3 PURCHASED DATABASE:
• 3.4 SECONDARY SOURCES:
  • 3.4.1 SECONDARY RESEARCH DATA FLOW:
• 3.5 PRIMARY RESEARCH:
  • 3.5.1 PRIMARY RESEARCH DATA FLOW:
  • 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
• 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
  • 3.6.1 REVENUE ANALYSIS APPROACH
• 3.7 DATA FORECASTING
  • 3.7.1 DATA FORECASTING TECHNIQUE
• 3.8 DATA MODELING
  • 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
  • 3.8.2 DATA MODELING:
• 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

• 4.1 INTRODUCTION
• 4.2 DRIVERS
  • 4.2.1 RISING GERIATRIC POPULATION
  • 4.2.2 FAVORABLE GOVERNMENT REGULATIONS
  • 4.2.3 GROWING DEMAND FOR DATA-DRIVEN TECHNOLOGIES
• 4.3 RESTRAINT
  • 4.3.1 RISK OF DATA PRIVACY
  • 4.3.2 HIGH COST OF IMPLEMENTATION
• 4.4 OPPORTUNITIES
  • 4.4.1 ADVANCEMENTS IN THE HEALTHCARE IT SECTOR

5 MARKET FACTOR ANALYSIS

• 5.1 VALUE CHAIN ANALYSIS
  • 5.1.1 INPUTS
  • 5.1.2 DESIGN & DEVELOPMENT
  • 5.1.3 OUTPUT
  • 5.1.4 SALES & DISTRIBUTION
  • 5.1.5 POST-SALES SERVICES
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 BARGAINING POWER OF SUPPLIERS
  • 5.2.2 BARGAINING POWER OF BUYERS
  • 5.2.3 THREAT OF NEW ENTRANTS
  • 5.2.4 THREAT OF SUBSTITUTES
  • 5.2.5 INTENSITY OF RIVALRY
• 5.3 IMPACT OF COVID-19 ON THE GLOBAL CLINICAL DECISION SUPPORT SYSTEM MARKET
  • 5.3.1 OVERVIEW
  • 5.3.2 IMPACT ON SUPPLY CHAIN
  • 5.3.3 IMPACT ON DEVELOPMENT
  • 5.3.4 IMPACT ON REGIONS
  • 5.3.5 MANAGING POST-COVID CARE THROUGH CLINICAL DECISION SUPPORT SYSTEMS

6 GLOBAL CLINICAL DECISION SUPPORT SYSTEM MARKET, BY PRODUCT

• 6.1 OVERVIEW
• 6.2 SOFTWARE
• 6.3 SERVICES
• 6.4 HARDWARE

7 GLOBAL CLINICAL DECISION SUPPORT SYSTEM MARKET, BY PRODUCT

• 7.1 OVERVIEW
• 7.2 INTEGRATED CDSS
• 7.3 STANDALONE CDSS

8 GLOBAL CLINICAL DECISION SUPPORT SYSTEM MARKET, BY MODEL

• 8.1 OVERVIEW
• 8.2 KNOWLEDGE-BASED CDSS
• 8.3 NON-KNOWLEDGE-BASED CDSS

9 GLOBAL CLINICAL DECISION SUPPORT SYSTEM MARKET, BY DELIVERY MODE

• 9.1 OVERVIEW
• 9.2 ON-PREMISE CDSS
• 9.3 CLOUD-BASED CDSS

10 GLOBAL CLINICAL DECISION SUPPORT SYSTEM MARKET, BY MODE OF ADVICE

• 10.1 OVERVIEW
• 10.2 ACTIVE CDSS
• 10.3 PASSIVE CDSS

11 GLOBAL CLINICAL DECISION SUPPORT SYSTEM MARKET, BY SETTING

• 11.1 OVERVIEW
• 11.2 INPATIENT SETTINGS
• 11.3 AMBULATORY CARE SETTINGS

12 GLOBAL CLINICAL DECISION SUPPORT SYSTEM MARKET, BY TYPE

• 12.1 OVERVIEW
• 12.2 THERAPEUTIC CDSS
• 12.3 DIAGNOSTIC CDSS

13 GLOBAL CLINICAL DECISION SUPPORT SYSTEM MARKET, BY APPLICATION

• 13.1 OVERVIEW
• 13.2 ADVANCED CDSS
• 13.3 CONVENTIONAL CDSS

14 GLOBAL CLINICAL DECISION SUPPORT SYSTEM MARKET, BY REGION

• 14.1 OVERVIEW
• 14.2 NORTH AMERICA
  • 14.2.1 US
  • 14.2.2 CANADA
• 14.3 EUROPE
  • 14.3.1 GERMANY
  • 14.3.2 FRANCE
  • 14.3.3 UK
  • 14.3.4 ITALY
  • 14.3.5 SPAIN
  • 14.3.6 REST OF EUROPE
• 14.4 ASIA-PACIFIC
  • 14.4.1 CHINA
  • 14.4.2 JAPAN
  • 14.4.3 INDIA
  • 14.4.4 AUSTRALIA
  • 14.4.5 SOUTH KOREA
  • 14.4.6 REST OF ASIA-PACIFIC
• 14.5 REST OF THE WORLD
  • 14.5.1 MIDDLE EAST & AFRICA
  • 14.5.2 LATIN AMERICA

15 COMPETITIVE LANDSCAPE

• 15.1 INTRODUCTION
• 15.2 MARKET SHARE ANALYSIS,
• 15.3 COMPETITOR DASHBOARD
• 15.4 PUBLIC PLAYERS STOCK SUMMARY
• 15.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
• 15.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 15.6.1 /PRODUCT/SOLUTION/SERVICE LAUNCHAPPROVAL
  • 15.6.2 COLLABORATION
  • 15.6.3 ACQUISITION
  • 15.6.4 PARTNERSHIP

16 COMPANY PROFILES

• 16.1 SIEMENS
  • 16.1.1 COMPANY OVERVIEW
  • 16.1.2 FINANCIAL OVERVIEW
  • 16.1.3 PRODUCTS OFFERED
  • 16.1.4 KEY DEVELOPMENTS
  • 16.1.5 SWOT ANALYSIS
  • 16.1.6 KEY STRATEGIES
• 16.2 VERADIGM LLC (ALLSCRIPTS HEALTHCARE SOLUTIONS INC)
  • 16.2.1 COMPANY OVERVIEW
  • 16.2.2 FINANCIAL OVERVIEW
  • 16.2.3 PRODUCTS OFFERED
  • 16.2.4 KEY DEVELOPMENTS
  • 16.2.5 SWOT ANALYSIS
  • 16.2.6 KEY STRATEGIES
• 16.3 ORACLE CORPORATION
  • 16.3.1 COMPANY OVERVIEW
  • 16.3.2 FINANCIAL OVERVIEW
  • 16.3.3 PRODUCTS OFFERED
  • 16.3.4 KEY DEVELOPMENTS
  • 16.3.5 KEY STRATEGIES
• 16.4 IBM
  • 16.4.1 COMPANY OVERVIEW
  • 16.4.2 FINANCIAL OVERVIEW
  • 16.4.3 SOLUTION OFFERED
  • 16.4.4 KEY DEVELOPMENTS
  • 16.4.5 SWOT ANALYSIS
  • 16.4.6 KEY STRATEGIES
• 16.5 CARESTREAM HEALTH
  • 16.5.1 COMPANY OVERVIEW
  • 16.5.2 FINANCIAL OVERVIEW
  • 16.5.3 SERVICE/SOLUTION OFFERED
  • 16.5.4 KEY DEVELOPMENTS
  • 16.5.5 KEY STRATEGIES
• 16.6 WOLTERS KLUWER N.V.
  • 16.6.1 COMPANY OVERVIEW
  • 16.6.2 FINANCIAL OVERVIEW
  • 16.6.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • 16.6.4 KEY DEVELOPMENTS
  • 16.6.5 SWOT ANALYSIS
  • 16.6.6 KEY STRATEGIES
• 16.7 EPIC SYSTEMS CORPORATION
  • 16.7.1 COMPANY OVERVIEW
  • 16.7.2 FINANCIAL OVERVIEW
  • 16.7.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • 16.7.4 KEY DEVELOPMENTS
  • 16.7.5 SWOT ANALYSIS
  • 16.7.6 KEY STRATEGIES
• 16.8 CHANG HEALTHCARE
  • 16.8.1 COMPANY OVERVIEW
  • 16.8.2 FINANCIAL OVERVIEW
  • 16.8.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • 16.8.4 KEY DEVELOPMENTS
  • 16.8.5 KEY STRATEGIES
• 16.9 MEDICAL INFORMATION TECHNOLOGY, INC.
  • 16.9.1 COMPANY OVERVIEW
  • 16.9.2 FINANCIAL OVERVIEW
  • 16.9.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • 16.9.4 KEY DEVELOPMENTS
  • 16.9.5 KEY STRATEGIES
• 16.10 COMPUTER PROGRAMS AND SYSTEMS, INC.
  • 16.10.1 COMPANY OVERVIEW
  • 16.10.2 FINANCIAL OVERVIEW
  • 16.10.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • 16.10.4 KEY DEVELOPMENTS
  • 16.10.5 KEY STRATEGIES

17 DATA CITATIONS